Back To Normal? US FDA Schedules In-Person Meeting But Pauses Non-COVID Guidance Development

 
• By Derrick Gingery
Compass and keyboard
FDA's recent actions seem to be aiming at different points on the compass as it assesses how the pandemic is affecting operations.

More from US FDA

More from Agency Leadership